OSLO,
Norway, April 29, 2022 /PRNewswire/ -- Navamedic
ASA (OSE: NAVA) publishes its annual report for 2021. The report is
attached and available on navamedic.com/investors. Additionally,
the company's Annual Report in European Single Electronic Format
(ESEF) is attached, please refer to the zip-file.
For further information, please contact:
Kathrine Gamborg Andreassen
CEO
Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand
CFO
Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
Navamedic ASA is a Nordic pharma company and reliable provider
of high-quality products, delivered to hospitals and through
pharmacies, meeting the specific needs of patients and consumers by
leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in
all the Nordic countries, the Baltics and Benelux, with sales
representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com
This information is subject to the disclosure requirements
pursuant to section 5 -12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic--annual-report-2021,c3556510
The following files are available for download:
|
https://mb.cision.com/Main/17619/3556510/1571604.pdf
|
Navamedic ASA Annual
report 2021
|
|
https://mb.cision.com/Main/17619/3556510/1571607.zip
|
NavamedicASA-2021-12-31-en.zip
|
